Intellia Therapeutics, Inc.
5.14 %
-63.57 %
Yet to be announced
Company Overview
Intellia Therapeutics, Inc. is a leading biotechnology company focused on developing curative genome editing treatments using CRISPR/Cas9 technology. The company aims to develop therapeutics for genetic diseases, cancers, and autoimmune conditions. They are pioneering in vivo and ex vivo cell therapies and have multiple candidates in clinical trials.
Revenue Sources
PassIntellia Therapeutics generates revenue primarily from collaboration agreements and research activities in genome editing therapeutics. Their business model and revenue sources are focused on developing innovative medical treatments using CRISPR technology. There are no identifiable haram revenue sources in their business model.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Dec. 31, 2024 | $12.87m | $149.32m | - | - | 0.00% | 0.00% |
| Sept. 30, 2024 | $9.11m | $153.88m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $6.96m | $146.0m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $28.93m | $142.94m | - | - | 0.00% | 0.00% |
The company is still in its R&D phase and pre-revenue stage for its main products. During the examination period, both interest income and interest expense were reported as $0 across all quarters. Since the company is pre-revenue and primarily in R&D mode, we skip the interest ratio calculations as they would not reflect the company's mature operating state.
Operational Ethics
PassBased on available information from SEC filings and company disclosures, there is no evidence of significant ongoing associations with entities involved in human rights violations. The company's operations and research facilities are primarily located in the United States and Europe, with no identified presence or ongoing projects in Israel or direct ties to the Chinese Communist Party.
Comments